stats FreshPatents Stats
1 views for this patent on
2012: 1 views
Updated: April 21 2014
newTOP 200 Companies filing patents this week

    Free Services  

  • Enter keywords & we'll notify you when a new patent matches your request (weekly update).

  • Save & organize patents so you can view them later.

  • RSS rss
  • Create custom RSS feeds. Track keywords without receiving email.

  • View the last few months of your Keyword emails.

  • Patents sorted by company.


Follow us on Twitter
twitter icon@FreshPatents

Ethanamine compounds and methods of using the same

last patentdownload pdfdownload imgimage previewnext patent

20120277272 patent thumbnailZoom

Ethanamine compounds and methods of using the same

(S)-2-methyl-1-phenyl-2-(pyridin-2-yl)propan-1-amine, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, uses of said compound or salt for therapy of depression and other conditions, and methods of treating depression and other conditions by administering said compound or salt.

Browse recent Astrazeneca Ab patents - Sodertalje, SE
Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John P. McCauley, Lihong Shen, David Nugiel
USPTO Applicaton #: #20120277272 - Class: 514357 (USPTO) - 11/01/12 - Class 514 
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) >Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai >Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms >Nitrogen Attached Indirectly To The Six-membered Hetero Ring By Nonionic Bonding

view organizer monitor keywords

The Patent Description & Claims data below is from USPTO Patent Application 20120277272, Ethanamine compounds and methods of using the same.

last patentpdficondownload pdfimage previewnext patent


This is a Continuation in Part of application Ser. No. 13/219,892 filed on Aug. 29, 2011 which is a Continuation of application Ser. No. 12/644,046 filed on Dec. 22, 2009, now U.S. Pat. No. 8,013,165, which claims the benefit of Provisional Application No. 61/140,673 filed on Dec. 24, 2008.


Disclosed herein is at least one ethanamine derivative, at least one pharmaceutical composition comprising at least one ethanamine derivative disclosed herein, and at least one method of using at least one ethanamine derivative disclosed herein for treating depression. The compounds may also have utility in the treatment of other diseases, including Parkinson\'s disease, pain states, such as neuropathic pain, as well as epilepsy and neurotrauma.


Depression is a common mental disorder that occurs in persons of all genders, ages, and backgrounds, affecting about 121 million people worldwide. Symptoms of depression include, but are not limited to, depressed mood, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, low energy, and poor concentration, or any combination thereof. These problems can become chronic or recurrent and lead to substantial impairments in an individual\'s ability to take care of his or her everyday responsibilities.

Depression is the leading cause of disability as measured by Years Lived with a Disability (YLDs) and the fourth leading contributor to the global burden of disease as measured by Disability Adjusted Life Years (DALYs; i.e., the sum of years of potential life lost due to premature mortality and the years of productive life lost due to disability) in 2000. By the year 2020, depression is projected to reach second place in the ranking of DALYs calculated for all ages, in both men and women. Today, depression is already the second cause of DALYs in the age category 15-44 years for both sexes combined. Whereas there are clearly a number of currently available treatments for depression, a significant proportion of patients are either incompletely treated (many residual symptoms remain) or do not respond to treatment at all. Thus, novel treatments for depression are needed. The present invention provides compounds, compositions, methods of preparing the same, and methods of treating depression. Such compounds would have additional utility in other disorders as well, including pain, Parkinson\'s disease, epilepsy and neurotrauma.



The present invention provides in this continuation-in-part application compounds 1-(3-fluorophenyl)-2-methyl-2-(pyridin-2-yl)propan-1-amine or a pharmaceutically acceptable salt thereof. (R)-1-(3-fluorophenyl)-2-methyl-2-(pyridin-2-yl)propan-1-amine or a pharmaceutically acceptable salt thereof. (S)-1-(3-fluorophenyl)-2-methyl-2-(pyridin-2-yl)propan-1-amine or a pharmaceutically acceptable salt thereof 2-methyl-1-phenyl-2-(pyridin-2-yl)propan-1-amine or a pharmaceutically acceptable salt thereof. (R)-2-methyl-1-phenyl-2-(pyridin-2-yl)propan-1-amine or a pharmaceutically acceptable salt thereof. (S)-2-methyl-1-phenyl-2-(pyridin-2-yl)propan-1-amine or a pharmaceutically acceptable salt thereof described throughout the application and in more detail in Examples 7 to 16.


The features and advantages of the invention may be more readily understood by those of ordinary skill in the art upon reading the following detailed description. An advantage of the present invention is the prevention of stilbazole formation. Stilbazole is an undesirable by-product. The effects of stilbazole on humans is not yet fully appreciated but a product without stilbazole would be preferable.

It is to be appreciated that certain features of the invention that are, for clarity reasons, described in the context of separate embodiments, may also be combined to form a single embodiment. Conversely, various features of the invention that are, for brevity reasons, described in the context of a single embodiment, may also be combined so as to form sub-combinations thereof.

Unless specifically stated otherwise herein, references made in the singular may also include the plural. For example, “a” and “an” may refer to either one, or one or more.

Embodiments identified herein as exemplary are intended to be illustrative and not limiting.

Unless otherwise indicated, any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.

Download full PDF for full patent description/claims.

Advertise on - Rates & Info

You can also Monitor Keywords and Search for tracking patents relating to this Ethanamine compounds and methods of using the same patent application.
monitor keywords

Keyword Monitor How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Ethanamine compounds and methods of using the same or other areas of interest.

Previous Patent Application:
Methods and compositions
Next Patent Application:
Small molecule inhibitors of rgs proteins
Industry Class:
Drug, bio-affecting and body treating compositions
Thank you for viewing the Ethanamine compounds and methods of using the same patent info.
- - - Apple patents, Boeing patents, Google patents, IBM patents, Jabil patents, Coca Cola patents, Motorola patents

Results in 0.81552 seconds

Other interesting categories:
Computers:  Graphics I/O Processors Dyn. Storage Static Storage Printers -g2--0.819

FreshNews promo

stats Patent Info
Application #
US 20120277272 A1
Publish Date
Document #
File Date
Other USPTO Classes
International Class

Follow us on Twitter
twitter icon@FreshPatents